Key facts
- It has raised $30.1M; the latest was Later Stage VC ($14.5M) in Mar 2026.
- Notable investors include Green Pine Capital Partners, Daan Incubator, Yuecai Zhongyin Private Equity Investment Fund Management (Guangdong).
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for CellGenes
- ·The full record, as it builds
Funding rounds
No funding rounds for CellGenes are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CellGenes
Manufacturer of stem cell-based therapeutic technologies designed to advance regenerative medicine and address diseases with limited treatment options. The company offers proprietary stem cell engineering platforms, scalable cell expansion and differentiation capabilities, and clinically validated translational pathways, enabling hospitals, clinical research institutions, and pharmaceutical partners to achieve safer cell therapies, broader disease coverage, and effective clinical application.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2016
- Website
- cellgenes.com/
- Ownership
- Privately Held (backing)
CellGenes doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CellGenes shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CellGenes in its N-PORT filings yet. We sweep new filings monthly.